Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

Sirtex Medical Ltd. (ASX:SRX) named Kevin Smith CEO. He was interim CEO and, before that, the cancer therapy company's EVP, sales & marketing for the Americas. Prior to joining Sirtex, Smith was EVP of business development at Gel-e Inc.

Stem cell therapy company Magenta Therapeutics Inc. (NASDAQ:MGTA) hired Jan Pinkas as SVP, translational sciences. He was head of translational R&D at Immunogen Inc. (NASDAQ:IMGN). The company also said CSO Mike Cooke is leaving to pursue other opportunities...